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Abstract
Background: Using in vivo mouse models, the mechanisms of CD4
+ T cell help have been intensively investigated. However,
a mechanistic analysis of human CD4
+ T cell help is largely lacking. Our goal was to elucidate the mechanisms of human
CD4
+ T cell help of CD8
+ T cell proliferation using a novel in vitro model  .
Methods/Principal Findings: We developed a genetically engineered novel human cell-based artificial APC, aAPC/mOKT3,
which expresses a membranous form of the anti-CD3 monoclonal antibody OKT3 as well as other immune accessory
molecules. Without requiring the addition of allogeneic feeder cells, aAPC/mOKT3 enabled the expansion of both peripheral
and tumor-infiltrating T cells, regardless of HLA-restriction. Stimulation with aAPC/mOKT3 did not expand Foxp3
+ regulatory
T cells, and expanded tumor infiltrating lymphocytes predominantly secreted Th1-type cytokines, interferon-
this aAPC-based system, the presence of autologous CD4
+ T cells was associated with significantly improved CD8
+ T cell
expansion in vitro. The CD4
+ T cell derived cytokines IL-2 and IL-21 were necessary but not sufficient for this effect. However,
CD4
+ T cell help of CD8
+ T cell proliferation was partially recapitulated by both adding IL-2/IL-21 and by upregulation of IL-
21 receptor on CD8
+ T cells.
Conclusions: We have developed an in vitro model that advances our understanding of the immunobiology of human CD4
+
T cell help of CD8
+ T cells. Our data suggests that human CD4
+ T cell help can be leveraged to expand CD8
+ T cells in vitro.
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Introduction
It is now well accepted that neoplastic cells are immunogenic
and that tumors develop in the context of immune recognition by
the host [1,2]. Tumor-associated antigens that serve as immune
targets include cell lineage differentiation antigens, cancer-testes
antigens, and neoantigens produced by mutations in the cancer
cell’s unstable genome. Mutational events can give rise to multiple
immunogenic MHC class I and II restricted, non-self epitopes
capable of inducing strong immune responses to the tumor [3,4].
In several maligancies, anti-tumor T cell responses, with
infiltration of tumors by CD8
+ T lymphocytes and local
production of interferon-c and IL-2, have been associated with
improved clinical prognosis [5–8].
Counter regulatory immune responses, however, also develop in
the cancer-bearing host. Tumors subvert the immune response by
secreting chemotactic factors that recruit immune suppressive
elements, thereby inhibiting the function of anti-tumor effectors
[9]. Tumor infiltration by T regulatory (Treg) cells has been
correlated with inferior clinical outcomes in several tumors
[10,11]. These findings have led to the proposal that immune
recognition of cancer involves the balancing of opposing forces:
anti-tumor effectors vs. pro-tumor regulatory elements [10,12,13].
In fact, a high ratio of Treg cells to CD8
+ T cells within the tumor
microenvironment has been associated with poorer survival
[14,15].
Adoptive T cell therapy is a promising treatment modality
designed to amplify the anti-tumor immune response. Anti-tumor
effectors are expanded in vitro, away from the pro-tumor milieu of
the cancer bearing host, and then reinfused as a cellular therapy
[16–21]. Successful approaches showing clinical activity include
adoptive transfer of tumor antigen-specific T cell lines or clones
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c   and IL-2. Inthat have been derived from the peripheral blood. Specificity can
be achieved by stimulating antigen-specific precursor T cells or
through genetic modification of expanded bulk T cells to express
cloned or chimeric T cell receptor (TCR) genes [22–26].
Alternatively, the nascent, endogenous immune effector response
to the tumor can be amplified by expanding tumor-infiltrating
lymphocytes (TIL) in vitro. Adoptive cell transfer of in vitro activated
TIL has achieved major clinical responses when patients first
undergo lymphodepletion and are then given high dose IL-2 after
adoptive transfer [17,27]. Lymphodepletion augments the persis-
tence and function of transferred TIL not only by reducing or
temporarily eliminating Treg cells, but also by reducing cytokine
sinks that results in the accumulation of homeostatic cytokines
such as IL-7 and IL-15 [28,29].
The optimal method for generating clinically effective T cell
grafts in vitro has yet to be established [21,30]. In order to achieve
massive numerical expansion of T cells, current methods
necessitate the use of soluble monoclonal antibodies (mAb),
allogeneic feeder PBMC, EBV transformed lymphoblastoid cell
lines, and/or undefined culture supernatants. Consequently, these
requirements present formidable challenges and costs that prevent
the widespread clinical application of this therapy. While adoptive
transfer of anti-tumor CD4
+ T cells can be efficacious, expansion
of anti-tumor CD8
+ T cells is also an important goal, particularly
in light of the association between their persistence and clinical
responses [18,31–33].
Insights into requirements for augmenting the expansion of both
CD4
+ and CD8
+ T cells will help further improve methods to
generate T cell grafts for adoptive therapy. CD4
+ T cells help
generate effective immune responses by sustaining CD8
+ T cell
proliferation, preventing exhaustion, and establishing long-lived
functional memory [34]. In mouse models, common c-chain
receptor cytokine and CD40 signaling can mediate CD4
+ T cell
help [34–44]. In clinical studies, CD4
+ T cells have also been
implicated in promoting the persistence and anti-tumor activity of
antigen-specific CD8
+ T cells in patients [45,46]. However, the
mechanisms of human CD4
+ T cell help are less well understood.
To conduct a mechanistic analysis of human CD4
+ T cell help, we
developed a novel, human cell-based aAPC, aAPC/mOKT3,
which induces both CD4
+ and CD8
+ T cell expansion without
allogeneic feeder cells. The removal of allogeneic feeder cells from
our T cell culture system enabled us to precisely isolate molecules
mediating help of CD8
+ T cell expansion that are expressed or
secreted by human CD4
+ T cells.
Results
K562-based aAPC expressing membranous OKT3 induces
CD3
+ T cell expansion
We and others have previously reported the generation of aAPC
derived from the human erythroleukemia cell line K562 [47–51].
K562 serves as an excellent platform for generating aAPC since it
expresses no HLA class I or II molecules, but highly expresses
adhesion molecules such as CD54 and CD58. Using K562, we
developed a novel aAPC, aAPC/mOKT3, capable of expanding
CD3
+ T cells regardless of HLA subtype (Figure 1A, Figure S1).
This aAPC was engineered to express a membranous form of the
anti-CD3 mAb, OKT3, on its cell surface, thus obviating the need
for adding soluble mAb to T cell cultures or loading it onto aAPC
as described elsewhere [51,52]. aAPC/mOKT3 also ectopically
expresses immunostimulatory molecules CD80 and CD83. We
and others have shown that CD83 delivers a CD80 dependent
signal that promotes lymphocyte longevity [47,53,54].
Stimulation of CD3
+ T cells with aAPC/mOKT3 induces
robust CD8
+ T cell expansion
Peripheral CD3
+ T cells expanded with aAPC/mOKT3 were
phenotypically characterized after 28 days in culture (Figure 2).
While the number of both CD4
+ and CD8
+ T cells increased, CD8
+
T cells expanded substantially better than CD4
+ T cells, and
therefore dominated cultures from every donor tested (Figure 2A).
This is in contrast to other pan T cell expansion systems such as
anti-CD3/CD28 mAb-coated beads, which invariably favor the
expansion CD4
+ T cells over CD8
+ T cells [55] (Figure 2B). Similar
fold expansion of CD3
+ T cells was obtained with the aAPC/
mOKT3-based and antibody-coated bead-based expansion sys-
tems. T cells expanded using aAPC/mOKT3 displayed a central
memory,effector memory phenotype (CD45RA
- CD54RO
+
CD62L
+/-) and retained expression of receptors for IL-2, IL-7,
and IL-21 (Figure 2C). CD40 ligand was highly expressed by CD4
+
T cells but not CD8
+ T cells. Importantly, expanded CD4
+ CD25
+
T cells did not express Foxp3, indicating that immunoinhibitory
Treg cells did not proliferate well (Figure 2D).
aAPC/mOKT3 induces unbiased CD3
+ T cell expansion,
preserving the repertoire for viral and tumor-associated
antigens
In order to evaluate whether stimulation with aAPC/mOKT3
induced broad expansion of CD3
+ T cells, TCR Vb repertoire
analysis was performed. No obvious skewing in the TCR Vb usage
of both CD4
+ and CD8
+ T cell populations was revealed,
supporting ‘‘unbiased’’ T cell expansion by aAPC/mOKT3
(Figure 3A). Moreover, HLA-restricted antigen-specific CD8
+
cytotoxic T lymphocytes (CTL) against viral and tumor antigens
could be generated from CD3
+ T cells initially expanded for four
weeks using aAPC/mOKT3 (Figure 3B and 3C). The functional
avidity of these tumor antigen-specific T cells was sufficient to
recognize tumor targets endogenously expressing antigen, con-
firming that the T cell repertoire for tumor antigen recognition
was preserved (Figure 3C). We also confirmed that stimulation
with aAPC/mOKT3 induced the expansion of tumor-antigen
specific T cells. After 28 days in culture, MART1 peptide specific
CD8
+ T cell expansion was 420–1,150 fold (Figure S1D).
Figure 1. Generation of aAPC/mOKT3. Surface expression of a
transduced membranous form of anti-CD3 mAb, and transduced CD80,
CD83, and endogenous HLA class I, class II, CD54, and CD58 on aAPC/
mOKT3 is shown. A membranous form of anti-CD3 mAb on aAPC/mOKT3
(open) and wild type K562 (shaded) was stained using goat anti-mouse
IgG (H+L). Other surface molecules were stained with each specific mAb
(open) andisotypecontrol(shaded) andanalyzed by flowcytometry.Note
the lack of endogenous expression of HLA class I and II on aAPC/mOKT3.
doi:10.1371/journal.pone.0030229.g001
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contaminating Treg cells
Using aAPC/mOKT3, lymphocytes derived from malignant
ascites (breast and ovarian cancer) and melanoma metastases
were successfully expanded without adding any allogeneic
feeder cells (Figure 4A). As observed with peripheral CD3
+ T
cells in Figure 2A, CD8
+ T cells predominantly expanded in all
cultures, including those that initially contained a minimal
percentage of CD8
+ Tc e l l s .I m p o r t a n t l y ,F o x p 3
+ cells did not
proliferate well (Figure 4B). As with peripheral CD3
+ T cells,
expanded TIL had a central memory,effector memory
phenotype (CD45RA
- CD62L
+/-) consistent with a lack of
terminal differentiation (FigureS 2 ) .F u r t h e r m o r e ,e x p a n d e dT
cells highly expressed CD27 and CD28 which are associated
Figure 2. aAPC/mOKT3 expands both CD4
+ and CD8
+ T cells without using allogeneic feeder PBMC. (A) CD3
+ T cells were stimulated
twice with aAPC/mOKT3 and supplemented with IL-2 between stimulations. Fold expansion of CD3
+ T cells over one month is shown for three
donors. Shading shows the proportion of expanded CD4
+ (white) and CD8
+ (black) T cells, and percent CD8
+ T cells is indicated. (B) CD3
+ T cells were
stimulated twice with aAPC/mOKT3 or beads (Dynabeads CD3/CD28) and supplemented with IL-2 between stimulations. Fold expansion of CD3
+ T
cells over one month is shown for three donors. Shading shows the proportion of expanded CD4
+ (white) and CD8
+ (black) T cells, and percent CD8
+
T cells is indicated. (C) CD3
+ T cells were expanded as described in Figure 2A. Expression of surface molecules on gated CD4
+ and CD8
+ T cells is
shown (open). Isotype mAb staining was used as a control (shaded). (D) CD4
+ CD25
+ Foxp3
+ Treg cells, present pre-expansion, were absent in
expanded cultures. CD4
+ CD25
+ cells, pre- and post-expansion, were stained intracellularly with anti-Foxp3 mAb (open) and isotype control (shaded).
doi:10.1371/journal.pone.0030229.g002
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secreted high quantities of IFN-c and IL-2, while IL-4 secretion
was lower and no IL-10 was produced (Figure 4C). These results
demonstrate that the aAPC/mOKT3-based system can expand
tumor-infiltrating CD8
+ T cells in the presence of autologous
CD4
+ T cells, and that they display phenotypic and functional
characteristics consistent with central memory,effector mem-
ory T cells.
IL-2 and IL-21 are necessary, but not sufficient, for CD4
+ T
cell-mediated help of CD8
+ T cell expansion
Using the aAPC/mOKT3-based expansion system, we com-
pared the expansion of CD8
+ T cells in the presence or absence of
CD4
+ T cells. CD8
+ T cells expanded much better in the presence
of CD4
+ T cells (Figure 5A), suggesting the presence of CD4
+ T
cell help for CD8
+ T cells in these aAPC/mOKT3-based cultures.
We tested whether this ‘‘help’’ was mediated by soluble factors or
Figure 3. Expansion with aAPC/mOKT3 does not induce skewing of the TCR Vb repertoire. (A) TCR Vb subfamily analysis before and after
stimulation with aAPC/mOKT3 is shown. CD3
+ T cells were stimulated with aAPC/mOKT3 on days 0 and 14 and were treated with IL-2 at 300 IU/ml
between stimulations. TCR Vb usage analysis was performed on days 0, 14, 28. Data shown is on gated CD4
+ and CD8
+ T cells. (B, C)A 2
+ CD3
+ T cells
were stimulated twice with aAPC/mOKT3 for one month. Subsequently, CD8
+ T cells were purified from expanded CD3
+ T cells and further stimulated
with aAPC/A2 pulsed with Flu or MART1 peptide. (B) Flu specificity was demonstrated by multimer staining (left). Functional competence was
demonstrated by antigen-specific cytotoxicity (middle) and IFN-c secretion (right). T2 cells pulsed with Flu peptide (&) or control peptide (N) were
used as targets. (C) MART1 specificity was similarly demonstrated by multimer staining (left). The HLA-A2
+/MART1
+ melanoma line, Malme-3M (&),
and the HLA-A2
+/MART1
- melanoma line, A375 (N), were used as targets in cytotoxicity (middle) and IFN-c ELISPOT assays (right).
doi:10.1371/journal.pone.0030229.g003
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breast and ovarian cancer ascites and melanoma metastases is shown. Shading indicates the proportion of CD4
+ (white) and CD8
+ (black) T cells in
expanded cultures. The percentage of CD8
+ T cells in pre- and post-expansion cultures is shown. Note that in all samples tested, the percentage of
CD8
+ T cells increased even in those that initially contained a minimal percentage of CD8
+ T cells. NT denotes not tested. (B) CD4
+ CD25
+ Foxp3
+ Treg
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stimulation, without any exogenously added cytokines, expanded
CD8
+ T cells by an average of 40.5% better when CD4
+ T cells
were present but separated from CD8
+ T cells by the transwell
membrane (P,0.005). In co-cultures where CD4
+ and CD8
+ T
cells were mixed, allowing for direct cell-cell contact, CD8
+ T cells
expanded more than in cultures where they were separated from
CD4
+ T cells by the transwell membrane (P,0.05). These results
suggest that observed CD4
+ T cell help involves both soluble
factors and cell-cell contact.
To identify molecules mediating the observed CD4
+ T cell help,
culture supernatants of CD4
+/CD8
+ T cell mixed and separate
cultures were tested for a panel of soluble factors (Figure 5C and
Table S1). Greater quantities of MIP-1a, MIP-1b, and RANTES
were detected in CD4
+/CD8
+ T cell mixed cultures compared to
separate cultures, suggesting increased production in mixed
cultures. In contrast, IL-2 and IL-21, as well as IL-10, IL-17,
TNF-a, and TNF-b, were detected at lower levels in mixed
cultures, consistent with more consumption or less production of
these cytokines.
Figure 5. Autologous CD4
+ T cell secretion of IL-2/IL-21 is necessary but not sufficient to help CD8
+ T cells proliferate. (A) CD8
+ T cells
were stimulated twice by aAPC/mOKT3 with or without CD4
+ T cells and treated with IL-2 between stimulations. Fold expansion of CD8
+ T cells over
28 days is shown for 3 donors. (B) CD8
+ T cells were stimulated only once by aAPC/mOKT3 with or without CD4
+ T cells in transwell plates. No IL-2 or
other cytokines were given. Fold expansion of CD8
+ T cells over 6 days is shown for 7 donors. (C) Culture supernatants were tested for a panel of
soluble factors to identify mediators of CD4
+ T cell help. Relative changes in cytokines, comparing mixed vs. separate cultures, are shown. Data is
representative of two donors. Absolute values for two donors are shown in Table S1. (D) Suppression of CD8
+ T cell expansion in the presence of
CD4
+ T cells by blocking reagents is presented as percent suppression relative to control. Values indicate mean of four independent experiments;
error bars show s.d. *P,0.005. (E) CD8
+ T cells were stimulated twice with aAPC/mOKT3 in the presence or absence of CD4
+ T cells. IL-2, IL-21, or both
were added in each condition. Fold expansion of CD8
+ T cells over 28 days is shown. Percent expansion was calculated by dividing the number of
expanded CD8
+ T cells by the number of CD8
+ T cells expanded in the presence of CD4
+ T cells. Values indicate mean of six independent
experiments; error bars show s.d.
doi:10.1371/journal.pone.0030229.g005
cells, present pre-expansion, were not detectable after one month of culture. CD4
+ CD25
+ cells were intracellularly stained with anti-Foxp3 mAb
(open) and isotype control (shaded). (C) IFN-c, IL-2, IL-4, and IL-10 secretion of expanded TIL was determined by ELISPOT assays. Cytokine secretion
by TIL from the breast cancer ascites specimen prior to expansion is shown as a control. Pre-expansion samples from melanoma and ovarian cancer
specimens were not studied because of low initial cell numbers.
doi:10.1371/journal.pone.0030229.g004
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production,’’ CD4
+/CD8
+ T cell mixed cultures were stimulated
in the presence of blocking reagents, and suppression of CD8
+ T
cell expansion was assessed (Figure 5D). Blockade of IL-2 and IL-
21 resulted in a reduction of expansion by 68.8% (P,0.005) and
42.9% (P,0.005), respectively. These results indicate that the
decreased levels of IL-2 and IL-21 in CD4
+/CD8
+ T cell mixed
cultures were due to more consumption rather than less
production and that these cytokines may be necessary mediators
of CD4
+ T cell help in this human-based in vitro system. To test
whether IL-2/IL-21 could substitute for the observed CD4
+ T cell
help, CD8
+ T cells stimulated with aAPC/mOKT3 were
supplemented with IL-2, IL-21, or both (Figure 5E). CD8
+ T
cells did not expand without IL-2. The addition of IL-2 with or
without IL-21 did not improve CD8
+ T cell expansion to the level
observed when cocultured with CD4
+ T cells, demonstrating that
IL-2 plus IL-21 are not sufficient to replace CD4
+ T cell help.
Exogenous IL-2/IL-21 and upregulation of IL-21 receptor
can partially recapitulate CD4
+ T cell help of CD8
+ T cell
expansion in vitro
Interestingly, we observed that higher expression of the IL-21
receptor (IL-21R) on CD8
+ T cells occurred when CD4
+ T cells
were present during stimulation by aAPC/mOKT3 (Figure 6A).
Higher IL-21R expression on CD8
+ T cells was not induced by
supplementing cultures with IL-2 and IL-21 (data not shown). This
prompted us to hypothesize that increased upregulation of IL-21R
on CD8
+ T cells is critical for the full effect of IL-21 secreted by
CD4
+ T cells. We constitutively expressed IL-21R on CD8
+ T
cells (Figure 6B, left) and stimulated them with aAPC/mOKT3 in
the presence of IL-2/IL-21. In accordance with the transduction
efficiency of IL-21R to 75.9%, CD8
+ T cell proliferation partially
increased to levels seen in the presence of CD4
+ T cells (Figure 6B,
right). This indicates that elevated expression of IL-21R is
necessary and can partially recapitulate CD4
+ T cell help for
CD8
+ T cell proliferation.
Discussion
A novel human cell-based aAPC expanded CD3
+ T cells in vitro
without the addition of allogeneic feeder PBMC. Phenotypic
analysis of expanded healthy donor T cells and TIL showed, that
while both CD4
+ and CD8
+ T cells expanded, CD8
+ T cells
predominated. In this model system, we demonstrated that CD8
+
T cell expansion depended on the presence of CD4
+ T cells,
suggesting that CD4
+ T cells provided help to proliferating CD8
+
T cells. The CD4
+ T cell secreted cytokines, IL-2 and IL-21, and
the CD4
+ T cell-dependent upregulation of IL-21R on CD8
+ T
cells were necessary for the observed CD4
+ T cell help.
Figure 6. IL-2/IL-21 and upregulation of IL-21R expression replace CD4
+ T cell help of CD8
+ T cell expansion in vitro. (A) IL-21R
expression on CD8
+ T cells stimulated with aAPC/mOKT3 in the presence or absence of CD4
+ T cells was studied by flow cytometry. On the left,
histogram plots for 1 donor is shown and, on the right, IL-21R expression on day 4 is displayed for 5 donors. (B) IL-21R expression on CD8
+ T cells
ectopically transduced with mock or IL-21R is shown (left). Expansion of transduced CD8
+ T cells stimulated twice by aAPC/mOKT3 with or without IL-
21 is compared (right). Percent expansion was calculated by dividing the number of expanded transduced CD8
+ T cells by that of CD8
+ T cells
stimulated in the presence of CD4
+ T cells. Values indicate mean of four independent experiments; error bars show s.d. *P,0.005.
doi:10.1371/journal.pone.0030229.g006
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+ T
cell help in murine in vivo studies. IL-2, one of the few effector
cytokines made by naı ¨ve CD4
+ T cells, expands activated T cells
and is essential in the development of CD8
+ T cell memory
responses to pathogens [60]. While CD8
+ T cell responses during
acute viral infections were relatively independent of IL-2, the
development of protective CD8
+ T cell memory responses
required IL-2 exposure during priming [35–37]. In vivo models
also indicate that IL-21 is critical for containing chronic viral
infections and preventing the deletion of high affinity antiviral
CD8
+ T cells. IL-21 secretion by CD4
+ T cells enables the
generation, sustained proliferation, and maintenance of polyfunc-
tional CD8
+ T cells during chronic infection [39–41].
Our results confirmed a role for IL-2 and IL-21 in human CD4
+
T cell help. By using a standardized aAPC, we were able to single
out and examine the effects of cocultured CD4
+ T cells,
unhindered by immunostimulatory and inhibitory factors pro-
duced by allogeneic feeder cells. Stimulation of T cells with aAPC/
mOKT3 induced the secretion of cytokines and chemokines,
including high levels of interferon-c, MIP-1a, and MIP-1b.
Among all the cytokines and chemokines studied, blocking
experiments identified IL-2 and IL-21 as necessary for CD4
+ T
cell help of CD8
+ T cell expansion. These cytokines alone,
however, were not sufficient to replace CD4
+ T cells. We showed
that CD4
+ T cells help by enhancing IL-21R expression on CD8
+
T cells, rendering them more responsive to secreted IL-21. Taken
together, the secretion of IL-2/IL-21 and the induction of IL-21R
are necessary and sufficient to partially recapitulate human CD4
+
T cell help of CD8
+ T cell expansion in vitro.
Transwell assays showed that the CD4
+ T cell dependent
expansion of CD8
+ T cells was also mediated by cell-cell contact
factors. CD40-CD40 ligand interactions have been shown to
mediate CD4
+ T cell help through CD40-mediated activation of
dendritic cells, which are then ‘‘licensed’’ to stimulate CD8
+ T
cells [43,44,61]. CD40 ligation was also shown to increase IL-21R
expression on B lymphocytes suggesting a mechanism for IL-21R
upregulation on CD8
+ T cells [62]. However, we did not observe
any suppression of CD8
+ T cell expansion following blockade of
CD40 ligand (Figure 5D) even though expanded CD4
+ T cells
strongly expressed CD40 ligand (Figure 2C). Furthermore,
stimulation with aAPC/mOKT3 in the presence of CD40 ligation
and the addition of IL-21 did not consistently enhance CD8
+ T
cell expansion (data not shown). Therefore, these results are in
agreement with others who have shown that CD4
+ T cells do not
provide direct help to CD8
+ T cells through CD40 ligation
[63,64]. It should be noted that blocking of CD70, 4-1BB, or
OX40 signaling also did not suppress the expansion of CD8
+ T
cells in the presence of CD4
+ T cells (Figure 5D).
aAPC induced polyclonal expansion of both CD4
+ and CD8
+ T
cells as shown by the absence of clonal skewing of the TCR Vb
repertoire. The ability to further expand antigen-specific T cells
capable of killing tumor targets indicated that the TCR repertoire
for highly avid T cells was preserved. Also, expanded TIL secreted
higher amounts of Th1 cytokines, IFN-c and IL-2, which are
associated with anti-tumor immunity. While aAPC/mOKT3
induced substantial expansion of CD8
+ T cells in the presence
of CD4
+ T cell help, terminal effector T cell differentiation did not
occur, as demonstrated by the central memory,effector memory
phenotype (CD45RA
- CD45RO
+ CD62L
+/-). Retention of
CD62L expression would enable homing to lymph nodes, where
encounter with antigen presented by professional APC could
augment immune responses [65]. CD27, which is down-regulated
in late stage effector T cells, was also highly expressed. CD27
expression by in vitro expanded TIL and T cell clones has been
associated with persistence and clinical responses after adoptive
transfer [56,57,59,66].
We also found that expanded T cells were not contaminated by
cells with the CD4
+ CD25
+ Foxp3
+ Treg phenotype even when
CD4
+ CD25
+ Foxp3
+ T cells were present prior to stimulation.
We previously found that K562-based aAPC expressing HLA-DR
molecules did not expand Foxp3
+ cells even though aAPC itself
produces modest amounts of the Treg cell growth factor TGF-b
[48]. We previously reported that aAPC also secretes IL-6 [47]. It
is possible that IL-6, secreted by aAPC, might interfere with
Foxp3
+ Treg cell expansion [67,68].
Adoptive transfer of in vitro expanded T cells has led to clinically
significant anti-tumor responses in patients [30]. By leveraging
autologous CD4
+ T cell help, aAPC/mOKT3 eliminates the use
allogeneic feeder cells for T cell expansion, potentially increasing
the availability of adoptive therapy as a cancer treatment. We
previously reported the development of K562-based aAPCs
dedicated to the expansion of HLA-restricted antigen-specific
CD4
+ and CD8
+ T cells [47,48]. Antigen-specific CD4
+ and
CD8
+ T cells expanded in vitro with these aAPC had a central
memory,effector memory phenotype (CD45RA
- CD62L
+/-) and
possessed surprisingly prolonged in vitro longevity without feeder
cells or cloning. In a recent clinical trial, HLA-A2-restricted
MART1 peptide-specific CD8
+ T cells generated in vitro with
aAPC were infused to advanced melanoma patients [69]. Without
lymphodepletion or IL-2 administration, transferred T cells could
persist for .16 months, established anti-tumor immunological
memory in vivo, trafficked to tumor, and induced clinical responses.
aAPC/mOKT3 extends the K562 platform to the stimulation of
T cells regardless of HLA subtype. The aAPC/mOKT3-based T
cell expansion system facilitates the understanding of mechanisms
for human CD4
+ T cell help and provides a novel strategy to
expand T cells for in vitro and in vivo uses.
Materials and Methods
Ethics Statement
All specimens and clinical data were collected under protocols
approved by the Institutional Review Board at the Dana-Farber
Cancer Institute (DFCI). All patients provided written informed
consent for the collection of samples and subsequent analysis.
cDNAs and cell lines
cDNAs encoding the heavy and light chains for a membranous
form of anti-CD3 mAb (OKT3, mIgG2a) were cloned from
hybridoma cells (ATCC, VA). HLA null K562 transduced with
CD80 and CD83 has been described previously [47,53]. CD80
+
CD83
+ K562 cells were retrovirally transduced with the heavy and
light chains of a membranous form of anti-CD3 mAb. After drug
selection, anti-CD3 mAb expressing cells were isolated by
magnetic bead guided sorting (Miltenyi Biotec, CA). High
expression of a membranous form of anti-CD3 mAb on the cell
surface was confirmed by flow cytometry. The parental cell line
K562 lacks the endogenous expression of any HLA molecule, but
does endogenously express the adhesion molecules CD54 and
CD58.
Retrovirus supernatants expressing IL-21R was harvested from
PG13 cells. Fresh CD8
+ T cells purified from healthy donors were
first activated with anti-CD3 (0.75 mg/ml) and anti-CD28 (1 mg/
ml) mAbs (Fitzgerald Industries International, MA) for two days.
Pre-activated T cells were infected with IL-21R or mock retrovirus
supernatants every 24 hr at an MOI of 10 for 10 days and treated
with 50 IU/ml IL-2 between infections. Following the assessment
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were stimulated with aAPC/mOKT3.
T2, A375, and Malme-3M cell lines were obtained from ATCC
as described elsewhere [47].
T cell expansion
Healthy donor PBMC were obtained by leukapheresis per-
formed at the DFCI Kraft Family Blood Donor Center. Cells were
isolated by Ficoll-Hypaque density gradient centrifugation and
CD3
+, CD4
+, or CD8
+ T cells were purified by negative selection
via MACS sorting according to the manufacturer’s protocol
(Miltenyi Biotec, CA). TIL samples were processed by centrifu-
gation of malignant ascites or mechanical and enzymatic digestion
of melanoma metastases with collagenase as previously described
[70]. CD3
+ TIL were obtained by positive or negative selection via
MACS sorting (Miltenyi Biotec, CA). aAPC/mOKT3 cells were
irradiated (200 Gy) and added to purified T cells at a T cell to
aAPC ratio of 20:1 unless otherwise noted. Dynabeads CD3/
CD28 (Invitrogen, CA) were used as stimulators according to the
manufacturer’s instruction at a T cell to bead ratio of 1:3.
Expanding T cells were cultured in RPMI 1640 containing 10%
human AB sera and gentamycin (Invitrogen, CA), and between
stimulations, unless otherwise noted, 300 IU/ml IL-2 (Prome-
theus, CA) was added every 3-4 days. In the absence of CD4
+ T
cells, CD8
+ T cells expanded only in the presence of IL-2. Where
indicated, 50 ng/ml IL-21 (Peprotech, NJ) was added every 3-4
days. Unless otherwise noted, T cells were restimulated every two
weeks. Expanded cells were characterized two weeks after the
second stimulation. Cell viability was .90% by trypan blue
exclusion.
To test whether antigen-specific cultures can be generated from
CD3
+ T cells polyclonally expanded with aAPC/mOKT3, CD3
+
T cells derived from HLA-A*0201 (A2)
+ donors were initially
stimulated and expanded with aAPC/mOKT3 for one month.
Subsequently, CD8
+ T cells were purified and further stimulated
with Flu or MART1 peptide-pulsed aAPC/A2 as previously
described [47,53].
Analysis of cultured T cells
Flow cytometry analysis was performed using mAbs for the
following antigens: CD4, CD8, CD25, CD28, CD56, CD62L, and
IL-2Rb (Coulter, CA); CD40 ligand, CD80, IL-7Ra, OX40,
OX40 ligand, and 4-1BB (BD Biosciences, CA); CD27, CD45RA,
CD45RO and CD83 (Invitrogen, CA); CCR4 and CCR7 (R&D
Systems, MN); ICOS, NKG2D, and PD-1 (eBioscience, CA);
CD38, Foxp3, HLA-DR, and 4-1BB ligand (Biolegend, CA);
CD40 and CD70 (Ancell, MN); IL-21R (R&D Systems, MN; or
BD Biosciences, CA). Goat anti-mouse IgG (H+L) Fab (Jackson
ImmunoResearch, PA) was used to detect surface expression of
murine Ig. Assessment of TCR Vb subfamily usage was performed
using TCR Vb mAbs (Beta Mark, Coulter, CA).
To assess the production/consumption of soluble factors in T
cell cultures, purified CD4
+, CD8
+, or a 1:1 mixture of CD4
+ and
CD8
+ T cells were stimulated with irradiated aAPC/mOKT3 for
72 hours and supernatants were measured for: GM-CSF, IFN-c,
IL-2, IL-4, IL-10, IL-12, IL-15, IL-17, MIP-1a, MIP-1b,
RANTES, TNF-a, TNF-b, and TRAIL (R&D Systems, MN);
IL-7 (Diaclone/Cell Sciences, MA); IL-18 (Medical & Biological
Laboratories, Japan); and IFN-a (PBL Biomedical Laboratories,
NJ). IL-21 (eBiosciences, CA) was measured at 48-hours. Relative
changes in cytokines resulting from mixed cultures of CD4
+ and
CD8
+ T cells vs. separate CD4
+ and CD8
+ T cell cultures were
determined by the following formula: (x-y)/y, where x=cytokine
secreted by CD4
+ and CD8
+ T cell mixed co-cultures and y is the
average of cytokine produced in separately stimulated CD4
+ and
CD8
+ T cell cultures.
IFN-c ELISPOT and standard chromium release assays were
performed as described elsewhere [47,53]. IL-2, IL-4 and IL-10
ELISPOT assays were performed according to the manufacturer’s
protocol (R&D Systems, MN).
Transwell and blocking assays
Transwell assays were performed by placing purified CD4
+,
CD8
+, or a mixture of CD4
+ and CD8
+ T cells into Millicell-24
plate chambers (Millipore) which were separated by a 0.4 mm filter
allowing free movement of soluble factors but not cells. T cells
were stimulated once with aAPC/mOKT3 in the absence of
exogenous cytokines. Six days later, expansion of CD8
+ T cells was
determined.
Blocking assays were performed in 96-well round bottomed
plates where CD4
+ and CD8
+ T cells were combined 1:1 and then
stimulated with irradiated mOKT3/aAPC in the presence of
blocking reagents. Blocking mAbs used recognized IL-2, IL-10, IL-
15, IL-17R, MIP-1a, MIP-1b, OX40 ligand, RANTES, TNFa,
and TNFb (R&D Systems, MN); 4-1BB (Neomarkers, CA); CD40
ligand (Biolegend, CA); and CD70 (Ancell, MN). IL-21 was
blocked using recombinant human IL-21R subunit/Fc chimeric
protein (R&D Systems, MN) as previously described [71]. Six days
later, CD8
+ T cell expansion was determined.
Statistical analysis
Data analysis was performed using the paired, one-sided
Student’s t-test where P,0.05 was considered to be statistically
significant.
Supporting Information
Figure S1 K562-based aAPC/mOKT3, expressing a
membranous form of anti-CD3 mAb, stimulates CD3
+
T cell expansion. (A) CD3
+ T cells were stimulated twice with
aAPC/mOKT3 and supplemented with IL-2 at the following
concentrations: 10 IU/ml (gray), 300 IU/ml (white) and 6,000
IU/ml (black). Fold expansion over 28 days is demonstrated.
Without IL-2 addition, T cell expansion over the 28-day culture
period was minimal. Data for three separate donors is shown. (B)
CD3
+ T cells were stimulated twice with aAPC/mOKT3 at the
indicated aAPC: T cell ratios. Cultures were supplemented with
IL-2 (300 IU/ml) between stimulations. Fold expansion of CD3
+ T
cells over one month is shown for two donors. (C) Phenotype of
fresh healthy donor CD3
+ T cells prior to stimulation is depicted
to compare with the T cells shown in Figure 2C which were
expanded with aAPC/mOKT3. Expression of surface molecules
on gated CD4
+ and CD8
+ T cells is shown (open). Isotype mAb
staining was used as a control (shaded). (D) HLA-A2
+ healthy
donor CD8
+ T cells were stimulated with MART1 peptide-pulsed
aAPC/A2 as previously described [47,53]. MART1 specific T
cells were then stimulated twice with aAPC/mOKT3 in the
presence of autologous CD4
+ T cells. Fold expansion of MART1
T cells over one month is shown for three donors.
(TIF)
Figure S2 TIL expanded with aAPC/mOKT3 express
CD27 and CD28 and have a central memory,effector
memory phenotype. CD3
+ T cells from malignant ovarian
ascites were stimulated twice with aAPC/mOKT3, and cultures
were supplemented with IL-2 at 300 IU/ml. (A) Fresh,
unstimulated TIL and (B) aAPC/mOKT3 expanded TIL were
stained with indicated mAb (open) and isotype control (shaded).
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on gated CD4
+ and CD8
+ T cells.
(TIF)
Table S1 Soluble factors in T cell cultures stimulated
with aAPC/mOKT3. Concentrations of soluble factors (pg/ml)
in supernatants of CD4
+ separate, or CD8
+ separate, and CD4
+
and CD8
+ mixed T cell cultures stimulated by aAPC/mOKT3
were measured by ELISA.
aPercent change was calculated as
detailed in Methods.
bnot applicable. Data from two different
donors is depicted.
(DOC)
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